Loading clinical trials...

Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies | Clinical Trials | Clareo Health

RECRUITINGPHASE3

Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

Med-RT BG: An Interventional Trial Using Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

NCT07166042•University of Utah

View on ClinicalTrials.gov

Summary

The goal of this study is to assess the effect of brief mindfulness-guided meditations during radiation therapy (RT) for patients with anxiety related to RT for breast and gynecological cancers.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participant aged ≥ 18 years.
•Diagnosis of breast or gynelogical cancer.
•Eligible to receive 15-25 daily radiation therapy treatments for breast or gynelogical cancer.
•Willing to participate in either the guided meditation or standard of care control arm, regardless of treatment assignment.
•Karnofsky performance score ≥ 60 or ECOG performance score ≤ 2.
•Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria

•Active suicidal ideation or active psychotic state in the opinion of the investigator.
•Patient is receiving deep inspiration breath hold treatment.
•An unstable illness that, in the opinion of the investigator, would interfere with study treatment.
•Prior radiation therapy.
•Inability to understand and/or speak the English language.

Locations (1)

Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, United States

Key Dates

Start Date

September 25, 2025

Primary Completion Date

September 30, 2027

Completion Date

September 30, 2028

Last Updated

October 3, 2025

Enrollment

ESTIMATED participants

Conditions

Breast CancerGynecologic Cancer

Interventions

10-15 minute, Audio-Recorded Guided Mediation Practices

BEHAVIORAL

Contacts

Rachel R. Kingford

CONTACT

801-585-0115 rachel.kingsford@hci.utah.edu

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812

Breast CancerHigh Risk of Breast Cancer

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

Inclusion Criteria

Exclusion Criteria

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer